← All trials
NCT05760248
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2023
- Primary completion
- Oct 28, 2024
- Completion date
- Dec 26, 2024
- First posted
- Mar 8, 2023
- Last posted
- May 23, 2023
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 10xBio, LLCLead sponsor
- Therapeutics, Inc.Collaborator
- 10xBio, LLCStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.